Skip to content

Study · Non-randomized trial · 1997

6 results

Growth hormone (GH) replacement reduces total body fat and normalizes insulin sensitivity in GH-deficient adults: a report of one-year clinical experience.

Hwu CM, Kwok CF, Lai TY, Shih KC, Lee TS, Hsiao LC, Lee SH, Fang VS, Ho LT

The Journal of clinical endocrinology and metabolism1 Oct 1997Cited by 71 (Europe PMC)

PMID9329355 (opens in a new tab)DOI10.1210/jcem.82.10.4311 (opens in a new tab)PepBankPUB-09329355
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, GH significantly reduced body fat percentage in the active arm.

    In plain wordsIn GH-deficient adults, GH reduced body fat percentage.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseBody fat percentage
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant reduction in fat % and total body fat mass was found in the active arm of period 1 without alteration of body weight.
    2 context sentences
    Summary · context
    The effects of GH replacement on body fat composition and insulin sensitivity were assessed in GH-deficient adults.
    Summary · context
    The patients were randomized into a double-blind, placebo-controlled study of human recombinant GH replacement therapy for 6 months (period 1), followed by an open phase of GH for another 6 months (period 2).
  2. 02HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, GH significantly reduced total body fat mass in the active arm.

    In plain wordsIn GH-deficient adults, GH reduced total body fat mass.

    Peptide
    HGH (somatotropin)
    Outcome
    DecreaseTotal body fat mass
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant reduction in fat % and total body fat mass was found in the active arm of period 1 without alteration of body weight.
    2 context sentences
    Summary · context
    The effects of GH replacement on body fat composition and insulin sensitivity were assessed in GH-deficient adults.
    Summary · context
    The patients were randomized into a double-blind, placebo-controlled study of human recombinant GH replacement therapy for 6 months (period 1), followed by an open phase of GH for another 6 months (period 2).
  3. 03HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, body weight did not change in the GH arm.

    In plain wordsIn GH-deficient adults, body weight did not change during GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBody weight
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Significant reduction in fat % and total body fat mass was found in the active arm of period 1 without alteration of body weight.
    2 context sentences
    Summary · context
    The effects of GH replacement on body fat composition and insulin sensitivity were assessed in GH-deficient adults.
    Summary · context
    The patients were randomized into a double-blind, placebo-controlled study of human recombinant GH replacement therapy for 6 months (period 1), followed by an open phase of GH for another 6 months (period 2).
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, GH replacement did not alter insulin sensitivity after 6 months.

    In plain wordsIn GH-deficient adults, GH did not change insulin sensitivity after 6 months.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeInsulin sensitivity
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Besides, we demonstrated, for the first time, the GH replacement for 6 months did not alter the insulin sensitivity, but replacement for a longer period (12 months) normalized not only the AM SSPG level but also the PM-AM SSPG pattern.
    2 context sentences
    Summary · context
    The effects of GH replacement on body fat composition and insulin sensitivity were assessed in GH-deficient adults.
    Summary · context
    The patients were randomized into a double-blind, placebo-controlled study of human recombinant GH replacement therapy for 6 months (period 1), followed by an open phase of GH for another 6 months (period 2).
  5. 05HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, GH replacement normalized morning steady-state plasma glucose after 12 months.

    In plain wordsIn GH-deficient adults, GH normalized morning steady-state blood glucose after 12 months.

    Peptide
    HGH (somatotropin)
    Outcome
    Direction not reportedMorning steady-state plasma glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Besides, we demonstrated, for the first time, the GH replacement for 6 months did not alter the insulin sensitivity, but replacement for a longer period (12 months) normalized not only the AM SSPG level but also the PM-AM SSPG pattern.
    3 context sentences
    Summary · context
    The modified insulin suppression test was performed both in the morning (AM) and in the afternoon (PM) to further evaluate the PM-AM steady-state plasma glucose (SSPG) pattern.
    Summary · context
    The effects of GH replacement on body fat composition and insulin sensitivity were assessed in GH-deficient adults.
    Summary · context
    The patients were randomized into a double-blind, placebo-controlled study of human recombinant GH replacement therapy for 6 months (period 1), followed by an open phase of GH for another 6 months (period 2).
  6. 06HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, GH replacement normalized the afternoon-minus-morning steady-state plasma glucose pattern after 12 months.

    In plain wordsIn GH-deficient adults, GH normalized the afternoon-minus-morning steady-state blood glucose pattern after 12 months.

    Peptide
    HGH (somatotropin)
    Outcome
    Direction not reportedAfternoon-minus-morning steady-state plasma glucose pattern
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Besides, we demonstrated, for the first time, the GH replacement for 6 months did not alter the insulin sensitivity, but replacement for a longer period (12 months) normalized not only the AM SSPG level but also the PM-AM SSPG pattern.
    3 context sentences
    Summary · context
    The modified insulin suppression test was performed both in the morning (AM) and in the afternoon (PM) to further evaluate the PM-AM steady-state plasma glucose (SSPG) pattern.
    Summary · context
    The effects of GH replacement on body fat composition and insulin sensitivity were assessed in GH-deficient adults.
    Summary · context
    The patients were randomized into a double-blind, placebo-controlled study of human recombinant GH replacement therapy for 6 months (period 1), followed by an open phase of GH for another 6 months (period 2).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT00136032

Growth Hormone Administration and Its Effects on Cardiovascular Risk Factors in Growth Hormone Deficient Women

Massachusetts General Hospitaln = 63Jan 2002 to Nov 2006

Growth Hormone Deficiency

Trial pageClinicalTrials.govUpdated 18 Feb 2008

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.